Cerebrovascular disease
Conditions
Interventions
Experimental group:low-dose rt-PA (0.6 mg/kg) + tirofiban
Control group:standard dose rt-PA (0.9 mg/kg)
Sponsors
Department of Neurology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.age = 18 years; 2.within 12 hours after the stroke onset or onset time unknow; 3.with a diagnosis of ischemic stroke and had definite symptoms of neurological impairment; 4.brain MRI showed DWI-FLAIR mismatch (MRI-DWI shows high signal intensity, but MRI-FLAIR shows no signal change or marginally high signal intensity in the relevant area); 5.no prior atrial fibrillation, severe heart disease and the possibility of cardiac embolism was excluded by CISS; 6.admission NIHSS score 0-20 points; 7.brain CT has ruled out intracranial hemorrhage before treatment; 8.patients or family members signed informed consent.
Exclusion criteria
Exclusion criteria: 1.brain MRI showed DWI-FLAIR matching (MRI-DWI shows high signal intensity, MRI-FLAIR also shows high signal intensity in the relevant area); 2. patients underwent endovascular procedure; 3. previous history of atrial fibrillation or severe heart disease and cardiac embolism could not be ruled out by CISS; 4. previous history of intracranial hemorrhage; 5. symptoms suggest subarachnoid hemorrhage; 6. existence of intracranial tumors, arteriovenous malformations or aneurysms; 7. nearly 3 months have a history of severe head injury or cerebral infarction, but does not include the old small lacunar infarction symptoms and signs; 8. nearly a week difficult to oppress the site of hemostasis arterial puncture; 9. severe liver and kidney dysfunction or severe diabetes; 10. accompanied by active bleeding; 11. blood glucose 185 mmHg or diastolic blood pressure> 110 mmHg; 13. acute bleeding tendency: platelet count less than 100×10^9/L; oral anticoagulant with INR>1.7; laboratory tests for abnormalities (such as APTT, TT, or factor Xa activity measurements) or other conditions; 14. admission NIHSS score >20 points
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Symptomatic intracranial hemorrhage; | — |
Secondary
| Measure | Time frame |
|---|---|
| NIHSS score;Early neurological deterioration;mRS score at three months after thrombolysis;Asymptomatic intracranial hemorrhage;Bleeding from other parts of the body;all-cause mortality; | — |
Countries
China
Contacts
Public ContactLiang Zhigang
Department of Neurology, the Affiliated Yantai Yuhuangding Hospital of Qingdao University
Outcome results
None listed